BI 1467335

Drug Profile

BI 1467335

Latest Information Update: 02 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Boehringer Ingelheim
  • Class Hepatoprotectants; Recombinant fusion proteins
  • Mechanism of Action AOC3 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-alcoholic steatohepatitis

Most Recent Events

  • 08 Aug 2017 Boehringer Ingelheim plans a phase II trial for Diabetic retinopathy in USA, France, Germany, Greece, Italy, Norway and United Kingdom (NCT03238963)
  • 12 Jul 2017 Boehringer Ingelheim completes a phase I trial in Non-alcoholic steatohepatitis (In volunteers) in Germany (NCT02733627)
  • 07 Jun 2017 Phase-I clinical trials in Non-alcoholic steatohepatitis (In volunteers) in Japan (PO) (NCT03159455)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top